2017 Year In Review

Views & Analysis

The UK pharma industry added its voice to calls for greater NHS funding in 2017 – but Brexit guaranteed there could be no rescue package

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.